Industry
Biotechnology
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
May 16, 2024 | 4:56 pm
Portfolio Pulse from Benzinga Newsdesk
May 14, 2024 | 2:02 pm
Portfolio Pulse from Benzinga Newsdesk
May 06, 2024 | 3:03 pm
Portfolio Pulse from Benzinga Newsdesk
May 03, 2024 | 7:53 pm
Portfolio Pulse from Benzinga Newsdesk
May 03, 2024 | 1:42 pm
Portfolio Pulse from Benzinga Newsdesk
May 02, 2024 | 9:11 pm
Portfolio Pulse from Benzinga Newsdesk
May 02, 2024 | 8:19 pm
Portfolio Pulse from Benzinga Newsdesk
April 22, 2024 | 5:45 pm
Portfolio Pulse from Benzinga Newsdesk
April 22, 2024 | 11:39 am
Portfolio Pulse from Benzinga Newsdesk
April 22, 2024 | 11:32 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.